Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Law firm cites Phospho-Soda package change

This article was originally published in The Tan Sheet

Executive Summary

The Laszlo & Associates law firm says C.B. Fleet Company has removed the "bowel cleanser" indication from the packaging for its nonprescription laxative after dozens of lawsuits were filed by people who suffered "acute renal failure and chronic kidney disease" after using the product as a bowel cleanser prior to colonoscopies and surgical procedures. In an Aug. 9 release, New York-based Laszlo says it is among the law firms representing clients from more than 20 states in suits against Lynchburg, Va.-based Fleet stemming from use of Phospho-Soda as a bowel cleanser. Following an FDA safety alert in May 2006, the firm recommended "follow the special instructions from your doctor exactly" when using its oral sodium phosphate products for bowel cleansing. FDA's announcement cited an association between bowel cleansers and acute phosphate nephropathy, a type of acute renal failure (1"The Tan Sheet" May 15, 2006, p. 10)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel